Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, ...
Jaguar Health, Inc.: Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste ...
FDA将讨论Jaguar Health乳腺癌治疗结果
Napo科学顾问委员会 (SAB)成员、转移性乳腺癌患者Kelly Shanahan博士表示，管理救命癌症药物引起的副作用至关重要。据Jaguar总裁兼首席执行官Lisa Conte称，克罗菲尔默在为接受靶向治疗的乳腺癌患者提供持续性腹泻改善方面比安慰剂更有效。
Jaguar Health’s Napo granted FDA Type C Meeting to discuss OnTarget study
Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified ...